Oncoinvent ASA, a clinical-stage radiopharmaceutical company developing innovative treatments for solid cancers, today announced positive final 24-month follow-up results from its Phase 1 clinical ...

To study how cells within high-grade serous ovarian cancer change over time, an MSK research team developed an approach they ...

The platinum-resistant ovarian cancer market is expanding due to a growing unmet need, as many patients relapse after first-line platinum therapies, driving demand for novel second- and later-line ...

Clinical trials pave the way for new cancer treatments. But they don't arise out of thin air. A new clinical trial for ovarian cancer patients at MUSC ...

Ovarian cancer management is challenging due to high morbidity and mortality, often from late-stage diagnoses. Advances in tumor genomics have led to targeted therapies, improving outcomes for ...

Ovarian cancer is one of the most challenging malignancies in oncology. Despite advances in diagnosis and treatment, it is still the deadliest gynaecologic cancer, claiming about 13,000 U.S. lives ...

Earlier this year at the American Society of Clinical Oncology (ASCO) Congress, pharmaphorum spoke with Redwood City, ...

AVMAPKI plus FAKZYNJA to be commercially available by prescription as a convenient oral combination co-packaged together and will be known as “AVMAPKI FAKZYNJA CO-PACK” Accelerated approval, well ...

A prospective, single-arm, phase 2 trial exploring the use of pamiparib combined with surufatinib as neoadjuvant therapy for advanced, unresectable ovarian cancer (PASSION). This is an ASCO Meeting ...

New Data Highlight Continued Potential of Radspherin to Prevent Disease Progression OSLO, Norway, Oct. 8, 2025 /PRNewswire/ -- Oncoinvent ASA, a clinical-stage ...

BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the ...